Immunomodulation in Administration of rAAV: Preclinical and Clinical Adjuvant Pharmacotherapies

Immunomodulation in Administration of rAAV: Preclinical and Clinical Adjuvant Pharmacotherapies

Recombinant adeno-associated virus (rAAV) has attracted a significant research focus for delivering genetic therapies to target cells. This non-enveloped virus has been trialed in many clinical-stage therapeutic strategies but important obstacle in clinical translation is the activation of both inna...

Full description

Bibliographic Details
Main Authors:	Wing Sum Chu, Joanne Ng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Immunology
Subjects:	immunomodulation immunosuppression immune response gene therapy adeno associated virus pharmacotherapies
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.658038/full

Similar Items

rAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates
by: Akiko Ishii, et al.
Published: (2020-09-01)

rAAV Manufacturing: The Challenges of Soft Sensing during Upstream Processing
by: Cristovão Freitas Iglesias, et al.
Published: (2023-02-01)

Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?
by: Wei Zhan, et al.
Published: (2021-05-01)

Optimization of miR-22 expression cassette for rAAV delivery on diabetes
by: Li Yang, et al.
Published: (2022-01-01)

Evading the AAV Immune Response in Mucopolysaccharidoses
by: Matthew Piechnik, et al.
Published: (2020-05-01)

PEG-mediated transduction of rAAV as a platform for spatially confined and efficient gene delivery
by: Liang Zou, et al.
Published: (2022-12-01)

Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate
by: Prashant Kumar, et al.
Published: (2023-09-01)

Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future
by: Hertanto DM, et al.
Published: (2021-07-01)

Molecular Signature of Astrocytes for Gene Delivery by the Synthetic Adeno‐Associated Viral Vector rAAV9P1
by: Amelie Bauer, et al.
Published: (2022-05-01)

High-Level rAAV Vector Production by rAdV-Mediated Amplification of Small Amounts of Input Vector
by: Stefan Weger
Published: (2022-12-01)

Durable transgene expression and efficient re-administration after rAAV2.5T-mediated fCFTRΔR gene delivery to adult ferret lungs
by: Yinghua Tang, et al.
Published: (2024-06-01)

rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
by: Artem A. Derkaev, et al.
Published: (2022-09-01)

Recombinant Adeno-Associated Virus Serotype 6 (rAAV6) Potently and Preferentially Transduces Rat Astrocytes in vitro and in vivo
by: Alexandra L. Schober, et al.
Published: (2016-11-01)

Red Blood Cell Anchoring Enables Targeted Transduction and Re‐Administration of AAV‐Mediated Gene Therapy
by: Zongmin Zhao, et al.
Published: (2022-08-01)

Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS
by: Marshall S. Goodwin, et al.
Published: (2020-03-01)

Transcriptome Profiling of Neovascularized Corneas Reveals miR-204 as a Multi-target Biotherapy Deliverable by rAAVs
by: Yi Lu, et al.
Published: (2018-03-01)

Comparison of highly pure rAAV9 vector stocks produced in suspension by PEI transfection or HSV infection reveals striking quantitative and qualitative differences
by: Prasad D. Trivedi, et al.
Published: (2022-03-01)

Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano)
by: Mélanie Demeules, et al.
Published: (2020-09-01)

A versatile toolkit for overcoming AAV immunity
by: Xuefeng Li, et al.
Published: (2022-09-01)

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
by: Ilias B. Esmagambetov, et al.
Published: (2023-03-01)

Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays
by: Thilo M. Buck, et al.
Published: (2020-06-01)

Impact of mechanical stimulation on the chondrogenic processes in human bone marrow aspirates modified to overexpress sox9 via rAAV vectors
by: Jagadeesh K. Venkatesan, et al.
Published: (2017-06-01)

Immunosuppression reduces rAAV2.5T neutralizing antibodies that limit efficacy following repeat dosing to ferret lungs
by: Yinghua Tang, et al.
Published: (2023-06-01)

Enriched Environment Cues Suggest a New Strategy to Counteract Glioma: Engineered rAAV2-IL-15 Microglia Modulate the Tumor Microenvironment
by: Alessandro Mormino, et al.
Published: (2021-09-01)

Plant Derived Immunomodulators; A Critical Review
by: Akey Krishna Swaroop, et al.
Published: (2022-08-01)

New Frontiers in Immunological Therapeutics in the Critically Ill Patient: From Immunosuppression to Immunomodulation
by: Jorge Luis Vélez Paez
Published: (2023-10-01)

rAAV9‐mediated supplementation of miR-29b improve angiotensin-II induced renal fibrosis in mice
by: Ju-hong Zhang, et al.
Published: (2021-08-01)

Preclinical Assessment of Immune Responses to AAV (adeno-associated virus) Vectors
by: Etiena eBasner-Tschakarjan, et al.
Published: (2014-02-01)

Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques
by: Liam Cole, et al.
Published: (2021-04-01)

VectorMOD: Method for Bottom-Up Proteomic Characterization of rAAV Capsid Post-Translational Modifications and Vector Impurities
by: Neil G. Rumachik, et al.
Published: (2021-04-01)

A Single Injection of rAAV-shmTOR in Peripheral Nerve Persistently Attenuates Nerve Injury-Induced Mechanical Allodynia
by: Minkyung Park, et al.
Published: (2023-11-01)

Transgene distribution and immune response after ultrasound delivery of rAAV9 and PHP.B to the brain in a mouse model of amyloidosis
by: Rikke Hahn Kofoed, et al.
Published: (2021-12-01)

Comprehensive mutagenesis maps the effect of all single-codon mutations in the AAV2 rep gene on AAV production
by: Nina K Jain, et al.
Published: (2024-03-01)

Establishment of a HEK293T cell line able to site-specifically integrate and stably express GDNF by rAAV-2 vector
by: Jinju Zhang, et al.
Published: (2016-07-01)

Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression
by: Lili Wang, et al.
Published: (2022-03-01)

Investigating the neuroprotective potential of rAAV2‐PCBP1‐EGFP gene therapy against a 6‐OHDA‐induced model of Parkinson's disease
by: Ling‐Yun Ma, et al.
Published: (2024-01-01)

Subgenomic particles in rAAV vectors result from DNA lesion/break and non-homologous end joining of vector genomes
by: Junping Zhang, et al.
Published: (2022-09-01)

rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
by: Weiran Shen, et al.
Published: (2022-10-01)

Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates
by: Unzu Carmen, et al.
Published: (2012-06-01)

Corrigendum: rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
by: Weiran Shen, et al.
Published: (2023-01-01)